BTBD9

BTBD9 is a substrate-recognition adaptor of the CUL3-RING (CRL3) E3 ubiquitin ligase complex that selects specific proteins for polyubiquitination and proteasomal degradation, linking it to processes ranging from cancer cell migration to insulin signaling and neuronal excitability [PMID:32327643, PMID:bio_10.1101_2025.05.15.654347]. As a CRL3 adaptor it directly binds and ubiquitylates TNFAIP1, and loss of BTBD9 stabilizes TNFAIP1 and enhances lung cancer cell migration (PMID:32327643); proteomic and ubiquitinome profiling identified IMPDH2 as an additional degradation substrate (PMID:35449961), and CUL3-BTBD9 ubiquitylates CAV1 in a step required for insulin-dependent AKT activation and myogenesis [PMID:bio_10.1101_2025.05.15.654347]. In the nervous system, BTBD9 shapes synaptic plasticity and excitability: knockout mice show enhanced hippocampal CA3-CA1 LTP with impaired presynaptic function and elevated dynamin 1 (PMID:22536397), cerebellar Purkinje cell hyperactivity through increased BK and decreased SK channel currents together with reduced SYNGAP1 (PMID:36244636), and altered corticostriatal transmission, where cortex-specific deletion alone produces rest-phase motor restlessness and cortical thinning (PMID:31715135). BTBD9 also regulates dopaminergic signaling, balancing the D1R and D2R pathways (PMID:32468214), and its C. elegans homolog hpo-9 protects dopaminergic neurons from manganese-induced oxidative stress by acting through the insulin/IGF-FOXO axis (PMID:35134179).

1. 2012 Medium

   Established the first mechanistic role for BTBD9 in the nervous system by asking whether it influences synaptic function, showing it constrains hippocampal plasticity and presynaptic machinery.

   Evidence Electrophysiology (LTP, PPF) and dynamin 1 western blot in Btbd9 gene-trap mutant mice with fear-memory behavior

   PMID:22536397

   Open questions at the time

   • Molecular link between BTBD9 and dynamin 1 regulation not defined
   • No biochemical mechanism connecting BTBD9 loss to LTP enhancement
2. 2019 Medium

   Tested whether BTBD9 function in a single brain region drives RLS-like phenotypes, demonstrating a cell-autonomous cortical role in motor behavior and corticostriatal transmission.

   Evidence Cortex-specific conditional Btbd9 KO with MRI, morphometry, corticostriatal electrophysiology, and behavior

   PMID:31715135

   Open questions at the time

   • Molecular substrates underlying cortical thinning unknown
   • Mechanism linking cortical BTBD9 loss to motor restlessness not resolved
3. 2020 High

   Identified the founding biochemical activity of BTBD9 as a CRL3 substrate-recognition adaptor, answering what BTBD9 does at the molecular level by linking it to targeted ubiquitination and a cancer migration phenotype.

   Evidence Quantitative proteomics, reciprocal Co-IP, in-cell ubiquitination assay, and TNFAIP1 deletion rescue in lung cancer cells

   PMID:32327643

   Open questions at the time

   • Degron/binding determinants on TNFAIP1 not mapped
   • Relationship between ubiquitin ligase activity and neuronal phenotypes not established
4. 2020 Medium

   Addressed how BTBD9 connects to dopamine signaling, placing it upstream of dopamine receptor expression and pathway balance across worm and mouse.

   Evidence C. elegans dopamine receptor reporter and epistasis assays plus qRT-PCR, western blot, and electrophysiology in Btbd9 KO mouse striatum

   PMID:32468214

   Open questions at the time

   • Direct ubiquitination targets in the dopaminergic pathway not identified
   • Mechanism of opposing D2R mRNA increase and protein decrease unexplained
5. 2022 Medium

   Expanded the BTBD9 substrate repertoire by asking what else CRL3-BTBD9 degrades, identifying IMPDH2 through unbiased ubiquitinome profiling.

   Evidence Quantitative proteomics plus diGly ubiquitinome profiling in BTBD9-overexpressing SH-SY5Y cells

   PMID:35449961

   Open questions at the time

   • No in vitro reconstitution or mutagenesis confirming direct ubiquitination
   • Physiological consequence of IMPDH2 degradation not tested
6. 2022 Medium

   Resolved a cell-autonomous mechanism for cerebellar dysfunction by linking BTBD9 loss to altered Ca2+-activated K+ channel currents and a candidate protein partner.

   Evidence Patch-clamp with BK/SK pharmacology, BK and SYNGAP1 western blot, and Purkinje-cell-specific conditional Btbd9 KO behavior

   PMID:36244636

   Open questions at the time

   • Whether BK/SYNGAP1 changes reflect direct ubiquitination is untested
   • BTBD9-SYNGAP1 association from single-lab Co-IP without reciprocal validation
7. 2022 Medium

   Defined a neuroprotective pathway for BTBD9 by asking how its homolog buffers metal-induced toxicity, showing it acts through the insulin/IGF-FOXO axis.

   Evidence C. elegans hpo-9 KO/overexpression, FOXO epistasis, oxidative stress and dopamine assays, AKT/FOXO western blot

   PMID:35134179

   Open questions at the time

   • Direct molecular substrate connecting BTBD9 to FOXO/AKT not identified
   • Conservation of this pathway in mammalian neurons not demonstrated
8. 2025 Medium

   Connected BTBD9 ubiquitin ligase activity to insulin signaling and muscle differentiation by identifying CAV1 as a substrate required for AKT activation.

   Evidence In vitro ubiquitylation assay, CUL3-BTBD9/CAV1 Co-IP, loss-of-function AKT readout, and myogenesis assay (preprint)

   PMID:bio_10.1101_2025.05.15.654347

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • In vivo relevance to muscle physiology not established

• It remains unknown which ubiquitination substrates underlie BTBD9's neuronal and behavioral phenotypes, linking its defined CRL3 enzymatic activity to its roles in synaptic plasticity and motor control.
• No substrate has been shown to mediate the LTP, Purkinje, or corticostriatal phenotypes
• Structural basis of substrate selection not determined